Fig. 1: CD38 expression is linked to EZH2 expression in MM cells.

A CD38 and EZH2 expression are significantly negatively correlated (p < 0.05) in CoMMpass cohort (n = 674). B EZH2 is significantly differentially expressed between the responder and the non-responder patients of a cohort of MM patients at relapse treated with Daratumumab (**p < 0.01) (n = 97). C CD38 mRNA expression is associated with enrichments of active (H3K4me3) or inactive (H3K27me3) histone marks on CD38 promoter (9 HMCLs, ChIP-seq experiments obtained as described [11]).